Roche Holdings (RHHBF.PK): H1 net profit +39.4% to 5.94B Swiss francs ($6.34B), broadly in line...


Roche Holdings (RHHBF.PK): H1 net profit +39.4% to 5.94B Swiss francs ($6.34B), broadly in line with forecasts; sales +4% to 23.3B francs. Earnings boosted by its existing portfolio, recently launched cancer medicines Perjeta and Kadcyla, and the continued growth of its clinical laboratory business. Confirms its outlook for the year, and expects FY sales to grow in line with 2012, when revenues increased 7%, while EPS is likely to rise ahead of sales. Roche also expects to further raise its dividend this year. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs